| Overview |
| bs-5027R |
| Angiopoietin-like 4 Polyclonal Antibody |
| WB, ELISA, IHC-P |
| Mouse |
| Human, Rat, Dog, Cow, Pig, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from mouse ARP4 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4_. Store at -20_ for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 57875 |
| Q9Z1P8 |
| Secreted, Extracellular matrix |
| Arp4; Bk89; Fiaf; Ng27; Pgar; Hfarp; Pgarg; Pp1158; Angiopoietin-related protein 4; 425O18-1; Angiopoietin-like protein 4; Fasting-induced adipose factor; Hepatic fibrinogen/angiopoietin-related protein; Secreted protein Bk89; Angptl4; Farp |
| Protein with hypoxia-induced expression in endothelial cells. May act as a regulator of angiogenesis and modulate tumorigenesis. Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. May exert a protective function on endothelial cells through an endocrine action. It is directly involved in regulating glucose homeostasis, lipid metabolism, and insulin sensitivity (By similarity). In response to hypoxia, the unprocessed form of the protein accumulates in the subendothelial extracellular matrix (ECM). The matrix-associated and immobilized unprocessed form limits the formation of actin stress fibers and focal contacts in the adhering endothelial cells and inhibits their adhesion. It also decreases motility of endothelial cells and inhibits the sprouting and tube formation. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
Powered by Bioz